# PhaseBio Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phasebio-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Malvern, US
- Website: www.phasebio.com
- Total disclosed funding: $111M
- Latest round: Series D (Aug 27, 2018)
- Investors on record: 10

## About

PhaseBio Pharmaceuticals, Inc., based in the US, focuses on developing innovative therapies for serious diseases. The company aims to address critical unmet medical needs through its proprietary drug candidates and unique technology platform.PhaseBio Pharmaceuticals, Inc. is dedicated to the development of therapies for serious medical conditions, specifically leveraging its half-life extending ELP technology platform. Founded in 2002 and headquartered in Malvern, Pennsylvania, US, the company has raised a total of USD 56.00 mn across multiple funding rounds. The most recent funding event was a Private Placement/Follow on in March 2021, which raised USD 56.00 mn. The CEO, Jonathan Mow, has led the company since its inception and has a background in biotechnology ventures. Notably, the company faced a restructuring process after filing for Chapter 11 bankruptcy protection in October 2022, resulting in the sale of its bentracimab program assets to SFJ Pharmaceuticals, Inc. for USD 32.9 mn in cash, completed in January 2023.PhaseBio Pharmaceuticals, Inc. specializes in developing innovative therapies that address critical needs in the biopharmaceutical sector. Their core product candidates focus on enhancing treatment options for serious diseases, primarily utilizing their proprietary ELP technology platform. The company serves a diverse clientele, including biotechnology firms and healthcare providers, positioning its solutions within North America and Europe to tackle specific industry challenges and regulatory requirements.In the most recent fiscal year 2021, PhaseBio Pharmaceuticals, Inc. reported revenue of USD 10.83 mn, with an EBITDA loss of USD 105.57 mn, indicating its ongoing investment in research and development activities essential for the advancement of its therapeutic programs.PhaseBio Pharmaceuticals, Inc. plans to utilize its recent funding of USD 56.00 mn to further the clinical development of its product candidates and to explore additional indications for its ELP technology platform. The company is focused on launching new therapies aimed at serious diseases, with specific emphasis on expanding its market presence in North America and Europe by 2024. The funding will support the necessary trials and regulatory submissions for these new products, enhancing their pipeline and providing innovative solutions to healthcare providers.

## Funding rounds

- Series D, Aug 27, 2018, $34M — New Enterprise Associates, Fletcher Spaght Ventures, AstraZeneca, Hatteras Venture Partners, Johnson & Johnson Innovation, Mountain Group Partners, Rock Springs Capital, Cormorant Asset Management, Syno Capital
- Series C, Jul 21, 2015, $1M — New Enterprise Associates, Fletcher Spaght Ventures, Hatteras Venture Partners, Johnson & Johnson Innovation
- Series C, Mar 12, 2015, $20M — New Enterprise Associates, Fletcher Spaght Ventures, AstraZeneca, Hatteras Venture Partners, Johnson & Johnson Innovation
- Series B, Jun 5, 2012, $23M — New Enterprise Associates, Fletcher Spaght Ventures, Astellas Venture Management, Hatteras Venture Partners, Johnson & Johnson Innovation
- Series C, Dec 2, 2010, $15M — New Enterprise Associates, Fletcher Spaght Ventures, Astellas Venture Management, Hatteras Venture Partners, Johnson & Johnson Innovation
- Series B, Dec 22, 2009, $10M — New Enterprise Associates, Fletcher Spaght Ventures, Astellas Venture Management, Hatteras Venture Partners, Johnson & Johnson Innovation
- Series B, Apr 21, 2008, $1M — Fletcher Spaght Ventures, Hatteras Venture Partners, Johnson & Johnson Innovation
- Series B, Nov 9, 2007, $5.4M — Fletcher Spaght Ventures, Hatteras Venture Partners, Johnson & Johnson Innovation
- Series B, Jan 2, 2007, $1M — Hatteras Venture Partners, Johnson & Johnson Innovation
- Series A, Aug 22, 2006, $0.3M — Hatteras Venture Partners
- Series A, Apr 28, 2004, $0.1M — Hatteras Venture Partners
- Series A, Feb 21, 2002, $0M — Hatteras Venture Partners

## Investors

- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A, Series B, Series C, Series D
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B, Series C, Series D
- Fletcher Spaght Ventures (https://capitalatlas.ai/funds/fletcher-spaght-ventures) — Series B, Series C, Series D
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series C, Series D
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series B, Series C
- AstraZeneca — Series C, Series D
- Mountain Group Partners (https://capitalatlas.ai/funds/mountain-group-partners) — Series D
- Rock Springs Capital — Series D
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series D
- Syno Capital (https://capitalatlas.ai/funds/syno-capital) — Series D